Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Alnylam And Tekmira Ink RNAi Delivery Pact
by Michael McCoy
August 10, 2009
| A version of this story appeared in
Volume 87, Issue 32
Alnylam Pharmaceuticals and Canada's Tekmira Pharmaceuticals have formed a research collaboration focused on the discovery of cationic lipids and lipid nanoparticles for the delivery of RNAi therapeutics. Both companies are already advancing RNAi drugs that use Tekmira's stable nucleic acid lipid particle delivery technology. Research will be funded by Alnylam and conducted by scientists at the University of British Columbia and at a newly formed company called AlCana Technologies.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X